Results from a first-in-human study suggest this new-look device could provide cardiologists and their care teams with another way to treat tricuspid regurgitation in high-risk patients.

Cardiovascular Associates of America, which calls Orlando home, has made increasing its presence in the Sunshine State a top priority in 2023.

The FDA has categorized this as a Class I recall, meaning the use of these devices could cause “serious injuries or death.”

ACC Vice President Cathleen Dalton Biga, MSN, RN, will serve as the group's next president. Cardiologist Christopher Kramer, MD, will be its next vice president. 

The new study, published in the Journal of the American College of Cardiology, focused on more than 500 patients treated with Abbott’s TriClip device in Europe.

A group of renowned TAVR specialists examined data from 783 pairs of intermediate-risk patients, sharing their findings in the Journal of the American College of Cardiology.

Ted Abraham, MD, explained why HCM has entered the limelight at recent cardiology conferences, including ASE 2023.

A new meta-analysis revealed that up to 26% of FEP patients display intracranial radiological abnormalities on MRI, some of which can alter clinical management.

At least 11 patients have come forward regarding severe complications stemming from treatments and procedures completed by "Dr. Roxy."